About Kerberos Proximal Solutions
Kerberos Proximal Solutions Inc., in Cupertino, Calif., developed proximal embolic-protection technology to recover debris dislodged during angioplasty and stent placement. The Kerberos device could lower significantly the embolic risk of these measures and make them more accessible to a broader patient population. The RCT BioVentures investment helped Kerberos perfect a mechanical model and demonstrate its use in animals. Kerberos received clearance from the U.S. Food and Drug Administration in September 2004 for coronary and peripheral use of the Rinspiration System. Rinspiration is focal simultaneous rinsing and aspiration administered by a single catheter. Later in the same month, Kerberos performed its 200th case of Rinspiration at New York Presbyterian/Columbia University Medical Center. The continued success of the Kerberos system in multi-device treatment interventions was one of the showcases highlighted at the IX Live Symposium of Complex Coronary and Cardiovascular Cases in New York in June 2006. In August 2006, FoxHollow Technologies ((Nasdaq: FOXH) announced a merger agreement to acquire Kerberos. Under the agreement, FoxHollow committed to pay about $32 million at closing, of which about $13 million it paid in stock.